Professional paper

https://doi.org/10.15836/ccar2017.28

The efficacy and safety of valsartan and the combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension — the VICTORY trial

Jure Berkopec ; Krka, d. d., Novo mesto, Slovenia
Anja Zaletel ; Krka, d. d., Novo mesto, Slovenia
Polona Knavs Vrhunec ; Krka, d. d., Novo mesto, Slovenia
Breda Barbič-Žagar orcid.org/0000-0002-1173-7361 ; Krka, d. d., Novo mesto, Slovenia

Abstract

Raised blood pressure (BP) is the leading global risk factor for cardiovascular disease and chronic kidney disease. Thus, in addition to lifestyle changes effective antihypertensive medication is clearly needed to provide not only symptomatic relief but also cardiovascular protection. The VICTORY trial was performed to assess the efficacy and safety of valsartan monotherapy (Valsacor®) and therapy with the fixed-dose combination (FDC) of valsartan and hydrochlorothiazide (Valsacombi®) in a broad population of patients with mild to moderate arterial hypertension. A total of 365 patients were enrolled in this 16-week, international, multicentre, open-label, prospective trial. The patients started the treatment with 80 mg valsartan daily, which could be up-titrated to 320 mg daily or combined with hydrochlorothiazide (HCTZ) in a fixed-dose combination to achieve target BP. The results of the VICTORY trial showed that valsartan and the FDC of valsartan and hydrochlorothiazide effectively reduce BP in patients with mild to moderate arterial hypertension, and have a very good tolerability profile.

Keywords

hypertension; blood pressure; efficacy; safety; valsartan

Hrčak ID:

179874

URI

https://hrcak.srce.hr/179874

Publication date:

28.2.2017.

Article data in other languages: croatian

Visits: 1.588 *